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A double-blind, randomized, placebo-controlled study was carried out
on 44 hypertensive type 2 diabetic subjects previously treated by diet
associated or not with sulfonylurea to assess the effects of acarbose-
induced glycemic control on blood pressure (BP) and hormonal
parameters. Before randomization and after a 22-week treatment
period (100 to 300 mg/day), the subjects were submitted to a standard
meal test and to 24-h ambulatory BP monitoring (ABPM) and had
plasma glucose, glycosylated hemoglobin, lipid profile, insulin, pro-
insulin and leptin levels determined. Weight loss was found only in the
acarbose-treated group (75.1 ± 11.6 to 73.1 ± 11.6 kg, P<0.01).
Glycosylated hemoglobin decreased only in the acarbose group (6.4 ±
1.7 to 5.6 ± 1.9%, P<0.05). Fasting proinsulin decreased only in the
acarbose group (23.4 ± 19.3 to 14.3 ± 13.6 pmol/l, P<0.05), while
leptin decreased in both (placebo group: 26.3 ± 6.1 to 23.3 ± 9.4 and
acarbose group: 25.0 ± 5.5 to 22.7 ± 7.9 ng/ml, P<0.05). When the
subset of acarbose-treated patients who improved glycemic control
was considered, significant reductions in diurnal systolic, diastolic
and mean BP (102.3 ± 6.0 to 99.0 ± 6.6 mmHg, P<0.05) were found.
Acarbose monotherapy or combined with sulfonylurea was effective
in improving glycemic control in hypertensive diabetic patients. Acar-
bose-induced improvement in metabolic control may reduce BP in
these patients. Our data did not suggest a direct action of acarbose on
insulin resistance or leptin levels.
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Approximately half of all diabetic pa-
tients are also hypertensive. One major fac-
tor linking diabetes and hypertension is insu-
lin resistance and/or hyperinsulinemia. Since
this situation is associated with increased
cardiovascular risk, antidiabetic agents - able
to reduce hyperinsulinemia - are desirable
for diabetic patients with hypertension. Obe-
sity contributes to elevated insulinemia and
is accompanied by high leptin levels (1,2).
Postprandial hyperglycemia, even in the
absence of fasting hyperglycemia, has been
shown to be an independent cardiovascular
risk factor (3,4). The properties of the an-
tidiabetic acarbose make this a promising
agent for the treatment of patients presenting
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hyperglycemia, hyperinsulinemia and hyper-
tension. Inhibition of α-intestinal glucosi-
dases by acarbose retards the absorption of
ingested carbohydrates and attenuates post-
prandial hyperglycemia and hyperinsuline-
mia. A potential beneficial effect of the drug
on insulin resistance due to the improvement
in hyperglycemia and glucotoxicity may also
contribute to reducing blood pressure (BP)
in hypertensive diabetic patients. However,
few data are available about the effects of
acarbose on BP, particularly using 24-h am-
bulatory monitoring, and on other hormonal
parameters, such as leptin levels (5).
The present study evaluated the effects
of acarbose-induced glycemic improvement
on BP and hormonal parameters in patients
at increased cardiovascular risk.
Patients and Methods
Fifty hypertensive diabetic patients aged
40-65 years were initially recruited from the
Diabetes and Hypertension Clinic of the Fed-
eral University of São Paulo. Written in-
formed consent was obtained from the pa-
tients and the study was approved by the
Institutional Ethics Committee. Inclusion
criteria were type 2 diabetes, BP between
140/90 and 160/104 mmHg and body mass
index (BMI) ≥27 kg/m2. Diabetic patients
were supposed to have been previously
treated by diet alone or associated with sul-
fonylurea; if they were treated with sulfonyl-
urea, this agent was maintained at the same
dose throughout the study. The use of other
oral antidiabetic agents and insulin was an
exclusion criterion. Antihypertensive thera-
py was based on salt intake restriction and if
pharmacological therapy was necessary (di-
astolic BP >105 mmHg after a 4-week wash-
out) only dipyridinic calcium channel
blockers (Adalat Oros®, Bayer, Leverkusen,
Germany) were used due to their neutrality
in terms of glucose metabolism (6); doses
(30 to 60 mg/day) were maintained through-
out the study period. Elevated serum creati-
nine and hepatic enzymes were also exclu-
sion criteria. Eligible patients were those
with fasting glycemia between 6.7 and 13.9
mmol/l and diastolic BP <95 mmHg at the
end of the placebo period. Of 50 patients
initially screened, 6 did not fulfill the inclu-
sion criteria.
This 24-week randomized, placebo-con-
trolled trial consisted of a 2-week placebo
period when patient eligibility was deter-
mined, followed by a 22-week double-blind
treatment period. Patients were advised about
a normocaloric diet and exercise and re-
ceived a placebo (half a tablet) twice a day
until randomization. Before starting the treat-
ment period, baseline anthropometric data
were obtained, 24-h ambulatory BP moni-
toring (ABPM) was performed, and a blood
sample for fasting plasma glucose, glycosyl-
ated hemoglobin, lipid profile, serum insu-
lin, proinsulin and leptin determinations was
taken. In addition, patients were submitted
to a standard meal test. Forty-four patients
were randomized to either the placebo group
or the acarbose group. The initial medication
dose was 50 mg (or half a tablet) twice a day,
adjusted at weeks 4 and 8 to 50 and 100 mg
twice a day, respectively, if fasting capillary
glycemia was >6.7 mmol/l. Thus, a maxi-
mum dose of 300 mg/day (3 tablets) was
reached in the acarbose group at week 8.
Weight, office BP and fasting capillary glu-
cose were checked at each follow-up visit
(weeks 4, 8, 12, 16 and 22). Treatment was
discontinued prematurely if fasting plasma
glucose level remained ≥13.9 mmol/l on two
consecutive visits. At the final visit, ABPM
and laboratory procedures were repeated to
detect changes from baseline. Patient com-
pliance was evaluated by counting the re-
maining tablets. Office BP was measured
during all visits at the same time of day by
the same investigator, using a standard mer-
cury sphygmomanometer with appropriate
cuff size. Ambulatory BP was recorded over
a 24-h period using automatic monitors
(SpaceLabs 90202, Redmond, WA, USA),
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set to record every 15 min during the day and
every 30 min during the night. Time limits
for day and night were set to coincide with
the patient’s usual sleeping hours. Night BP
fall was calculated by the percent difference
between day and night systolic BP. Standard
meal tests, performed after a 10-h fast, con-
sisted of the consumption of a liquid meal
(Ensure®, Abbott, Columbus, OH, USA) with
total energy of 251 kcal, containing 50% of
energy as carbohydrate, 15% as protein and
35% as fat. The morning tablet should be
taken during the meal test and postprandial
blood samples were obtained 1 h after con-
sumption for plasma glucose and hormonal
determinations.
Laboratory data (glycosylated hemoglo-
bin, lipid profile, albumin excretion rate,
fasting and postprandial plasma glucose, in-
sulin, proinsulin and leptin) were obtained at
baseline and at the end of the treatment
period. The insulin resistance index (IRI)
was estimated by the homeostasis model
assessment (7). Plasma glucose was deter-
mined by the glucose-oxidase method, gly-
cosylated hemoglobin by HPLC (normal
range: 2.5-4.3%) and triglyceride and cho-
lesterol contents of lipoprotein fractions were
measured enzymatically. Urinary albumin
was measured in duplicate by immunoturbi-
dimetric assay (UNIMATE 3 ALB®, Roche,
Basel, Switzerland). Insulin, proinsulin and
leptin were determined using a radioimmu-
noassay kit (Linco Research Inc., St. Charles,
MO, USA). The coefficients of variation of
the assays were <10%. Insulin cross-reactiv-
ity with proinsulin was <0.2%. Fasting refer-
ence values were 5-15 µU/ml for insulin and
7.9 ± 1.5 pmol/ml for proinsulin. Leptin
values for men and women were 3.8 ± 1.8
ng/ml and 7.4 ± 3.7 ng/ml, respectively.
Statistical analysis was performed using
the SigmaStat software package. Parametric
and nonparametric tests were used to com-
pare variables within (paired Student t-test
or Wilcoxon rank test) and between groups
(unpaired Student t-test or Mann-Whitney
U-test). Correlation between BMI and leptin
level was tested by the Pearson coefficient.
The chi-square test was used to compare
frequencies. The level of significance was
set at P<0.05.
Results
Forty patients completed the study; two
patients of each group were excluded due to
unstable diabetic control. One patient of each
group had hypoglycemic episodes, and their
sulfonylurea doses were reduced. Complaints
of flatulence (N = 6) and/or diarrhea (N = 3)
among acarbose-treated patients were attenu-
ated throughout the study and did not inter-
fere with the medication used. Compliance
ranged from 85-96% of the prescribed medi-
cation. The highest acarbose dose was given
to 17 of 20 patients who completed the study.
At baseline, demographic, clinical and
laboratory data were similar between groups
(Table 1). A significant reduction in body
weight was verified in the acarbose group
(75.1 ± 11.6 vs 73.1 ± 11.6 kg, P<0.01) but
not in the placebo group (80.2 ± 9.8 vs 79.3
± 9.7 kg, P = 0.10); the same occurred with
BMI (placebo group: 31.7 ± 3.9 vs 31.5 ± 3.7
kg/m2, P = 0.40 and acarbose group: 30.3 ±
Table 1. Baseline characteristics of the groups of patients.
Placebo group Acarbose group
Number of patients (men/women) 20 (8/12) 20 (6/14)
Age (years) 62.0 ± 9.7 59.8 ± 8.2
Diabetes duration (months) 81 (6-174) 82 (6-240)
Diabetes treatment (diet/SU) 6/14 7/13
Hypertension duration (months) 136 (24-240) 126 (12-360)
Micro- or macroproteinuria (yes/no) 10/10 12/8
Diabetic retinopathy (yes/no) 2/18 3/17
Weight (kg) 80.2 ± 9.8 75.1 ± 11.6
BMI (kg/m2) 31.7 ± 3.9 30.3 ± 2.9
Mean office BP (mmHg) 107.8 ± 6.7 101.7 ± 9.0
Fasting plasma glucose (mmol/l) 10.3 ± 3.8 9.6 ± 2.3
Glycosylated hemoglobin (%) 6.3 ± 2.1 6.4 ± 1.7
Creatinine (µmol/l) 84 ± 20 78 ± 16
Data are reported as means and standard deviations or median and range. Differences
were nonsignificant. SU, sulfonylurea; BMI, body mass index; BP, blood pressure.
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2.9 vs 29.8 ± 2.7 kg/m2, P<0.05). In acar-
bose-treated patients, weight reduction was
observed particularly in those under mono-
therapy (78.8 ± 10.2 vs 75.2 ± 8.3 kg, P<0.05)
but not in those under combined therapy
with sulfonylurea (73.1 ± 12.2 vs 72.0 ± 13.2
kg, P = 0.18). Fasting or postprandial glyce-
mia did not differ between groups at ran-
domization or at the end of the treatment
period (Table 2). A significant improvement
of glycosylated hemoglobin was observed
only in acarbose-treated patients. A tendency
to a lower increment of glycemia after the
meal test was observed in the acarbose group
at the end of treatment when compared with
the initial increment. Groups had similar
lipid and hormonal profiles at baseline. No
change in triglycerides, total, LDL- and HDL-
cholesterol, fasting and postprandial insulin
levels or IRI was found at the end of the
treatment period. IRI was reduced in 75% of
acarbose-treated subjects in contrast to 45%
in the placebo group (P = 0.11). Fasting
proinsulin levels were decreased only in the
acarbose group at the end of the study, but no
difference was observed in postprandial val-
ues. The proinsulin/insulin ratio did not
change at the end of the treatment periods
(placebo group: 0.15 ± 0.13 to 0.14 ± 0.15, P
= 0.77 and acarbose group: 0.24 ± 0.21 to
0.26 ± 0.34, P = 0.79). Leptin levels were
found to be correlated with BMI in women (r
= 0.50, P<0.05). Both groups had their leptin
levels reduced at the end of treatment (pla-
cebo group: 26.3 ± 6.1 to 23.3 ± 9.4 ng/ml
and acarbose group: 25.0 ± 5.5 to 22.7 ± 7.9
ng/ml, P<0.05).
Two patients from each group did not
require antihypertensive medication during
the placebo period. Office systolic, diastolic
and mean BP levels of the acarbose group
were slightly lower than those of the placebo
group (Table 3). Both groups had their office
BP reduced at the end of the study period,
although only the placebo group reached
statistical significance. Baseline BP levels
obtained by ABPM did not differ between
groups and no change in systolic, diastolic or
mean BP levels was found in any period.
Baseline heart rates and nocturnal BP falls
Table 2.  Metabolic and hormonal data obtained before randomization and at the end of the treatment period.
Placebo group  Acarbose group
Initial Final P Initial Final P
Fasting glycemia (mmol/l) 10.3 ± 3.7 10.0 ± 3.5 0.63 9.6 ± 2.3 9.8 ± 4.6 0.78
Postprandial glycemia (mmol/l) 15.6 ± 5.2 15.6 ± 5.1 0.98 14.3 ± 3.6 13.8 ± 5.9 0.61
Glycemic increment (%) 54.0 ± 21.0 62.0 ± 56.0 0.57 49.0 ± 17.0 41.0 ± 25.0 0.07
Glycosylated hemoglobin (%) 6.3 ± 2.1 6.3 ± 2.0 0.15 6.4 ± 1.7 5.6 ± 1.9 0.03
Total cholesterol (mmol/l) 12.2 ± 2.2 11.8 ± 1.7 0.19 11.4 ± 1.8 11.1 ± 2.2 0.34
HDL-cholesterol (mmol/l) 2.0 ± 0.4 1.9 ± 0.4 0.44 2.2 ± 0.6 2.2 ± 0.4 0.56
LDL-cholesterol (mmol/l) 8.4 ± 2.5 8.2 ± 1.4 0.47 7.7 ± 1.7 7.4 ± 1.7 0.34
Triglycerides (mmol/l) 10.8 ± 4.6 10.3 ± 4.9 0.45 7.9 ± 3.1 8.6 ± 4.5 0.37
Fasting insulin (µU/ml) 21.7 ± 10.6 21.8 ± 12.9 0.97 23.4 ± 18.6 18.0 ± 11.8 0.16
Postprandial insulin (µU/ml) 62.5 ± 52.0 49.0 ± 29.8 0.31 52.7 ± 32.0 59.2 ± 53.2 0.67
IRI 9.4 ± 5.0 7.9 ± 3.4 0.90 9.8 ± 6.8 7.2 ± 4.2 0.10
Fasting proinsulin (pmol/ml) 32.3 ± 28.7 27.7 ± 18.0 0.37 23.4 ± 19.3 14.3 ± 13.6 0.03
Postprandial proinsulin (pmol/ml) 47.9 ± 35.9 54.4 ± 29.3 0.38 49.8 ± 29.8 40.6 ± 28.1 0.26
Leptin (ng/ml)
Men 27.9 ± 6.9 26.9 ± 9.4 0.31 26.1 ± 5.1 23.4 ± 7.9 0.08
Women 25.8 ± 5.9 22.3 ± 7.4 0.01 24.6 ± 5.8 22.3 ± 8.1 0.01
Data are reported as means and standard deviations or median and range. IRI, insulin resistance index. P
values refer to the comparison of initial and final results (Student t-test).
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were also similar and did not change by the
end of the study. A comparison between
patients who lost weight (N = 11) or not (N =
9) during acarbose therapy showed no dif-
ference in BP values obtained by ABPM and
no correlation between body weight and BP
variations.
A subset of 11 patients from the acarbose
group who achieved improvement in meta-
bolic control (glycosylated hemoglobin fall)
was analyzed separately. Duration of diabe-
tes and initial plasma glucose levels were not
different when compared to the remaining
acarbose-treated patients; 64% showed a re-
duction in 24-h systolic BP (136.0 ± 6.0 to
132.1 ± 7.0 mmHg, P = 0.10) and 73% of this
subset showed a reduction in 24-h mean BP
(100.3 ± 6.0 to 97.6 ± 7.0 mmHg, P = 0.12).
These reductions were statistically signifi-
cant for diurnal systolic (138.0 ± 6.7 to 133.7
± 7.2 mmHg, P<0.03), diastolic (83.0 ± 7.6
to 80.0 ± 7.2 mmHg, P<0.05) and mean BP
(102.3 ± 6.0 to 99.0 ± 6.6 mmHg, P<0.05) at
the end of the treatment period, but not for
nocturnal values. The IRI of these patients
tended to decrease during treatment (7.9 ±
4.6 to 6.0 ± 5.0, P = 0.14).
Discussion
The results of this study indicate benefi-
cial effects of acarbose on glycemic control
of type 2 diabetic patients previously treated
with diet alone or associated with sulfonyl-
urea, since a significant reduction in glyco-
sylated hemoglobin (0.8%) was obtained.
Large prospective studies, in which acar-
bose was administered as monotherapy or in
combination with other antidiabetic agents,
also showed improvement in glycemic con-
Table 3. Hemodynamic data obtained before randomization and at the end of the treatment period.
Placebo group  Acarbose group
Initial Final P Initial Final P
Office BP
Systolic (mmHg) 148.5 ± 13.0 140.7 ± 12.0 0.02 140.2 ± 16.2 134.0 ± 11.9 0.13
Diastolic (mmHg) 87.6 ± 5.5 84.2 ± 5.4 0.01 82.5 ± 7.3 80.9 ± 4.5 0.32
Mean (mmHg) 107.8 ± 6.7 103.0 ± 6.8 0.02 101.7 ± 9.0 98.7 ± 6.3 0.17
ABPM
24-h
Systolic (mmHg) 138.0 ± 11.6 138.3 ± 11.1 0.86 134.4 ± 7.8 132.4 ± 9.0 0.15
Diastolic (mmHg) 81.5 ± 10.1 81.4 ± 7.9 0.96 80.1 ± 7.2 78.7 ± 7.7 0.16
Mean (mmHg) 101.4 ± 8.5 101.5 ± 6.6 0.94 99.2 ± 6.9 97.2 ± 7.7 0.06
Heart rate (bpm) 80.3 ± 8.2 78.9 ± 10.8 0.36 81.1 ± 8.0 79.8 ± 8.0 0.31
Day period
Systolic (mmHg) 136.7 ± 8.1 134.2 ± 9.8 0.38 136.7 ± 8.2 134.2 ± 9.8 0.08
Diastolic (mmHg) 82.2 ± 7.4 80.7 ± 8.2 0.53 82.2 ± 7.4 80.7 ± 8.2 0.14
Mean (mmHg) 101.2 ± 7.0 99.1 ± 8.2 0.40 101.2 ± 7.0 99.1 ± 8.2 0.06
Systolic load (%) 36.4 ± 22.2 31.5 ± 22.9 0.49 31.5 ± 22.9 36.4 ± 22.2 0.14
Diastolic load (%) 23.2 ± 18.0 17.5 ± 18.1 0.32 17.5 ± 18.1 23.2 ± 18.0 0.10
Night period
Systolic (mmHg) 130.8 ± 13.1 133.1 ± 13.1 0.42 127.0 ± 8.7 126.8 ± 10.1 0.92
Diastolic (mmHg) 74.7 ± 12.2 76.2 ± 9.5 0.39 72.7 ± 7.1 72.1 ± 7.7 0.62
Mean (mmHg) 94.8 ± 11.6 96.5 ± 9.1 0.44 91.9 ± 7.0 91.6 ± 8.5 0.84
Nocturnal BP fall (%) 8.3 ± 8.7 5.1 ± 8.1 0.25 7.7 ± 3.7 6.9 ± 4.8 0.25
Data are reported as means and standard deviations or median and range. BP, blood pressure; ABPM,
ambulatory blood pressure monitoring. P values refer to the comparison of initial and final results (Student t-
test).
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trol (8,9). A noncontrolled study including
4,071 patients reported a 1.0 to 2.3% de-
crease in glycosylated hemoglobin (8), which
was less in the PROTECT trial (9). The
comparison of our findings with those of
controlled studies, either vs placebo or vs a
reference drug, showed similar reductions in
glycosylated hemoglobin levels (10-12). In a
multicenter European study, glycosylated
hemoglobin dropped by 0.9% in patients on
acarbose monotherapy and on acarbose treat-
ment combined with sulfonylurea (10). Our
benefit was even better if compared to the
0.3-0.6% reductions achieved in the UKPDS
after 3 years of follow-up (13). The acar-
bose-induced decrease in glycosylated he-
moglobin strongly suggests that total daily
insulin secretion was reduced during the
study period. In addition to glycosylated he-
moglobin, the efficacy of acarbose was evalu-
ated by the glycemic response to oral over-
load of nutrients. No standardization con-
cerning the total energy to be consumed
during a meal test is found in the literature.
The Essen Study used a standardized break-
fast containing a total energy of 372 kcal
(11) but even higher caloric overloads have
been reported. In our study, acarbose thera-
py was associated with a smaller increase in
postprandial plasma glucose after an over-
load of 251 kcal, when compared with the
placebo group. This may suggest that the
groups of patients, with comparable respons-
es to the meal test at baseline, became dis-
tinct following acarbose therapy. However,
mean postprandial plasma glucose was not
changed by this therapy, in agreement with
some (13) but not all previous reports
(10,11,14).
Based on potential hemodynamic ben-
efits (5,15) related to the improvement in
metabolic control, as expressed by decreased
glycosylated hemoglobin, the effects of acar-
bose on BP of hypertensive diabetic patients
were investigated. Some experimental stud-
ies have provided contradictory results
(16,17). Comparison of baseline and final
office BP showed that patients had their BP
levels decreased throughout the study pe-
riod, being statistically significant only for
the placebo group. This suggests a white-
coat effect, which seemed to be minimized at
the final visit to the doctor. Based on 24-h
ABPM, acarbose-treated patients did not re-
duce BP. Considering the hypothesis of a
glycemic control-induced hypotensive effect,
we analyzed the subset of 11 patients with
reduced glycosylated hemoglobin. In con-
trast to the total group of acarbose-treated
patients, those with improved glycemic con-
trol had a significant BP drop in the diurnal
period and a borderline significant drop dur-
ing the 24-h  period, indicating a beneficial
role of glycemic control on BP levels of
diabetic hypertensive patients. The reason
for BP reduction only during the day re-
quires further investigation. Intensive moni-
toring of glucose and insulin levels, particu-
larly during the postprandial period, could
also help clarify this aspect. The lack of
correlation between weight and BP varia-
tions is against a role of weight loss in BP
reduction. Furthermore, when analyzing
separately the subset of patients from the
acarbose group who lost weight (N = 11),
quite similar baseline and final BP levels
were found. Thus, our data support the no-
tion of a hypotensive effect derived mainly
from the improvement in metabolic control
and attenuation of insulin resistance. To ex-
plore this possibility, insulin concentration
and the HOMA for insulin resistance were
assessed. Reductions in postprandial insuli-
nemia following acarbose therapy and im-
proved insulin sensitivity in patients with
impaired glucose tolerance were previously
reported (18). However, our findings do not
support the idea that acarbose could attenu-
ate insulin resistance and, consequently, re-
duce insulin secretion by the beta cells. The
fact that a considerable proportion of our
patients were on sulfonylurea should have
contributed to their unchanged insulin lev-
els. When the benefits of acarbose and/or
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tolbutamide were compared, acarbose mono-
therapy did not prove to reduce postprandial
hyperinsulinemia and tolbutamide alone was
associated with high postprandial insulin lev-
els when compared to the combination with
acarbose (12). Our finding of unchanged
postprandial insulinemia in the acarbose
group might be due to an opposite action of
sulfonylurea favoring insulin secretion. Pre-
vention of the weight gain that usually fol-
lows sulfonylurea administration, however,
could be considered an advantage of the
combination of acarbose in sulfonylurea-
treated patients. Although the comparison of
HOMA between groups does not indicate an
acarbose-induced improvement in insulin
sensitivity, considering the patients whose
IRI was decreased, a higher number of acar-
bose-treated patients (75%) showed im-
proved insulin sensitivity compared to pla-
cebo (45%).
The previously described correlation of
insulin levels with leptin (19) was not seen in
the present study. Adipose mass represents
the major determinant of leptin levels (20).
Although only the acarbose group exhibited
weight loss, both groups of patients showed
reduced leptin levels. The lack of an accu-
rate method to evaluate alterations in body
composition, mainly concerning percentage
of adipose mass, does not allow further specu-
lations.
Acarbose shows benefits in terms of the
glycemic control of hypertensive diabetic
patients previously treated with diet alone or
combined with sulfonylurea. Size sample
and combined therapy may have a limited
ability to demonstrate plasma glucose and
insulin responses to acarbose. The adminis-
tration of acarbose to sulfonylurea-treated
patients may prevent weight gain. Such ef-
fects are desirable taking into account the
elevated cardiovascular risk of these patients.
In addition, the improvement in metabolic
control induced by acarbose may contribute
to reducing BP as evaluated by 24-h ABPM.
Our data do not suggest a direct action of
acarbose on insulin resistance or leptin.
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